Skip to content

Establishment of a safe and effective ablation system for secondary hyperparathyroidism in chronic kidney disease

Establishment of a safe and effective ablation treatment system for hyperparathyroidism secondary to chronic kidney disease

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300069627
Enrollment
Unknown
Registered
2023-03-22
Start date
2023-04-01
Completion date
Unknown
Last updated
2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperthyroidism secondary to chronic kidney disease

Interventions

Group A:Stripping surrounding water isolation before ablation
Group B:Traditional liquid isolation
Group C:Ablation with 5mm working electrode not completely surrounded by water
Group D:Ablation with 7mm working electrode not completely surrounded by water

Sponsors

fujian provincial hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: efer to the guidelines of the Global Kidney Disease Prognosis Improvement Organization (KDIGO) [9] and the consensus of experts in clinical practice of surgery for hyperparathyroidism secondary to chronic renal failure: 1) dialysis patients with SHPT in phase 5 of chronic kidney disease; 2) In patients with resistance to calcium-sensitive receptor agonists, vitamin D and its analogues, continuous full-segment parathyroid hormone (PTH>800pg/ml; 3) 99mTc-MIBI dual-phase imaging and neck ultrasound showed hyperplastic parathyroid glands in all patients; 4) No severe bleeding disorder, cardiac discomfort or uncontrolled hypertension.

Exclusion criteria

Exclusion criteria: 1) 99mTc-MIBI dual-phase imaging found ectopic parathyroid glands outside the neck; 2) Patients with primary hyperparathyroidism. 3) Laryngoscopy showed abnormal vocal cord movement; 4) Abnormal coagulation function test (prothrombin time>25 seconds, prothrombin activity<40%, platelet count<100*109/L) 5) The patient refused the RFA; 6) Severe cardiopulmonary dysfunction;

Design outcomes

Primary

MeasureTime frame
intraoperative blood loss;Operation time;hospital stay;ablation time per unit volume;occurrence of recurrent laryngeal nerve;Parathyroid hormone levels;Serum calcium;

Secondary

MeasureTime frame
Serum C-reactive protein (CRP);tumor necrosis factor- a ( TNF- a);interleukin-6 (IL-6);

Countries

China

Contacts

Public ContactSongsong Wu

Fujian provincial hospital

465269898@qq.com15960191609

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026